ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Cancer

August 14, 2014
Laurie Fenton Ambrose, President and CEO of the Lung Cancer Alliance, discusses lung cancer screening from the patient’s perspective.
August 11, 2014
Data from 6 cohort studies were evaluated to assess the ongoing risk of mesothelioma more than 40 years after initial environmental exposure to asbestos.  Among over 22,000 of those exposed, 707 cases of pleural mesothelioma were diagnosed.  The rate and risk increased until 45 years after exposure, then the rate of increase tapered off somewhat.
August 9, 2014
This multiinstitutional randomized trial compared sublobar resection alone to sublobar resection with adjuvant brachytherapy in high risk patients with peripheral NSCLC <3cm.  Time to and type of local recurrence were similar between the groups.  Brachytherapy did not importantly improve local control in patients with potentially compromised margi
August 9, 2014
This single-institution retrospective study used propensity score matching to compare long-term outcomes of anatomic segmentectomy vs lobectomy for early stage non-small cell lung cancer.   A total of 312 pts were matched in each group.  Locoregional and overall recurrence rates were similar between the groups.  Freedom from recurrence (70% for segme
August 9, 2014
This randomized trial involving 30 centers in France compared outcomes after induction chemoradiotherapy followed by resection to resection alone for stage I or II esophageal cancer.  The R0 resection rate was similar between the groups.  Postoperative mortality was higher in the induction therapy group (11.1% vs 3.4%).  Long-term survival was simila
August 5, 2014
Optimal management of superior sulcus tumors remains challenging.  This SWOG protocol was a feasibility study of the utility of consolidation therapy with docetaxel in addition to cisplatin-etoposide, 45Gy, and possible resection.   Of 46 registered pts, 86% completed induction therapy, 66% underwent resection, and 45% completed consolidation therapy
July 29, 2014
Records of nearly 24,000 Australian patients with NSCLC were evaluated to determine the relationship between distance to the nearest speciality hospital (NASH) and survival.  Increasing distance from a NASH was associated with decreasing likelihood of admission to a NASH and decreasing likelihood of lung cancer resection, resulting in an increasing h
July 29, 2014
Using data from 2 centers in London, outcomes after induction therapy and resection for esophageal cancer were analyzed according to the pathological response to induction therapy.  Downstaging was the strongest predictor of survival (HR 0.43).  Downstaging was also associated with a lower rate of local recurrence (6% vs 13%) and systemic recurrence
July 28, 2014
The authors queried whether PET has utility in clinically staging Tis or T1 esophageal cancers; this was a single institution retrospective study involving 79 pts.  The incidence of FDG uptake increased with increasing T status, as did the SUV.  Nodal staging was false positive in 3 pts and false negative all 13 pts with nodal involvement.  Metastati
July 28, 2014
The efficacy of induction therapy for clinical T2 esophageal cancer was evaluated using the National Cancer Database.  Pretreatment staging was accurate in only 27% of pts.  42% of pts were upstaged and 32% were downstaged.  Induction therapy had no survival benefit.   

Pages